Regan, Jessica A.
Truby, Lauren K.
Tahir, Usman A.
Katz, Daniel H.
Nguyen, Maggie
Kwee, Lydia Coulter
Deng, Shuliang
Wilson, James G.
Mentz, Robert J.
Kraus, William E.
Hernandez, Adrian F.
Gerszten, Robert E.
Peterson, Eric D.
Holman, Rury R.
Shah, Svati H.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (1R38HL143612)
National Institutes of Health (T32HL069749)
Merck & Co.
Duke Center for the Study of Heart Failure and Diabetes (16SFRN31800010)
Article History
Received: 3 September 2022
Accepted: 11 November 2022
First Online: 22 November 2022
Competing interests
: R.J.M. received research support and honoraria from Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim/Eli Lilly, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Medtronic, Merck, Novartis, Relypsa, Respicardia, Roche, Sanofi, Vifor, and Windtree Therapeutics. A.F.H received research support and honoraria from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim/Eli Lilly, Boston Scientific, Cytokinetics, Merck, Myokardia, Novartis, Relypsa. R.R.H and E.D.P report relevant disclosures from Merck & Co. S.H.S. receives research funding through sponsored research agreements between AstraZeneca, Lilly Inc. and Project Baseline LLC with Duke University; has two unlicensed patents on unrelated research findings; and is the co-chair for the NIH HeartShare program. All other authors report no relationships with industry to disclosure.